Fig. 5: β-Glucan-mediated granulopoiesis requires type I IFN signaling.
From: β-Glucan reprograms neutrophils to promote disease tolerance against influenza A virus
WT and Ifnar1−/− mice were treated with β-glucan. a,b, Representative FACS plots (a) and total cell counts (b) of neutrophils in the BM. c, Frequency of neutrophils in the blood (n = 5). d,e, Representative FACS plots (d) and total cell counts of neutrophils (e) in the lungs at day 4 post-β-glucan treatment (n = 8). f,g, Survival of C57BL/6 WT (f) or Ifnar1−/− (g) mice after β-glucan treatment following IAV infection (lethal dose) at day 7. h, Mouse chimera model. i,j, Weight loss (i) and survival (j) of CD45.1 chimeric mice reconstituted with Ifnar1−/− (CD45.2) BM after β-glucan treatment following IAV infection (lethal dose) on day 7 (n = 10). Data are represented as mean ± s.e.m. Data were analyzed using two-way ANOVA followed by Šidák’s multiple-comparison tests (b, c, e and i). Survival was monitored by a log(rank) test (g and j). *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. Illustrations in f and h created using BioRender.com.
